{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Table 2', 'Pharmacokinetic, ATA and Biomarker Blood Sample Collection Time Points - Arm A', 'Blood', 'Biomarkers', 'Plasma', 'PBMC', 'Study Day', 'Time', 'Window', 'Relative Time', 'ATA', 'Pre-dose', 'within 24 hr', 'START of infusion', 'X', 'X', 'X', 'X', 'X', 'Day 1', 'End of infusion', 'Within 15 min', 'END of infusion', 'X', 'Cycles 1', 'Day 8', 'Pre-dose', 'Within 24 hrs', 'START of infusion', 'X', 'X', 'X', 'Day 15', 'Pre-dose', 'Within 24 hrs', 'START of infusion', 'X', 'X', 'X', 'End of infusion', 'Within 15 min', 'END of infusion', 'X', 'Cycle 2', 'Day 1', 'Pre-dose', 'Within 24 hrs', 'START of infusion', 'X', 'X', 'X', 'X', 'X', 'Cycles 3, 4, 6, 8 and 10', 'Day 1', 'Pre-dose', 'Within 24 hrs', 'START of infusion', 'XA', 'XA', 'XB', 'XC', 'XB', 'End of Treatment (Date of last dose + 7 days )', 'X', 'X', 'X', 'X', 'X', 'Follow-up (Date of last dose +30 days)', 'X', 'X', 'ATA: antitherapeutic antibodies; PBMC: peripheral blood mononuclear cells; cfDNA: circulating free deoxyribonucleic acid', 'A. Pharmacokinetics and ATA: Pre-dose of cycle 3, 4, 6, 8 and 10', 'B. Cytokines and Immuno-phenotyping: Pre-dose cycles 3 and 4 only', 'C. cfDNA: Pre-dose every even numbered cycle up to 10 cycles (e.g., cycle 4, 6, 8, 10)', '14 Sep 2020', 'Astellas', 'Page 36 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Table 3', 'Biomarker Blood Sample Collection Time Points - Arm B', 'Biomarkers', 'Plasma', 'PBMC', 'Study Day', 'Time', 'Window', 'Relative Time', 'Cycle 1', 'Day 1', 'Pre-dose', 'Within 24 hr', 'START of infusion', 'X', 'X', 'X', 'Cycle 2', 'Day 1', 'Pre-dose', 'Within 24 hr', 'START of infusion', 'X', 'X', 'X', 'Subsequent Dosing Cycles', 'Day 1', 'Pre-dose', 'Within 24 hr', 'START of infusion', 'XB', 'XA', 'XB', 'End of Treatment (Date of last dose + 7 days)', 'X', 'X', 'X', 'cfDNA: circulating free deoxyribonucleic acid; PBMC: peripheral blood mononuclear cells', 'A. cfDNA: Pre-dose every even numbered cycle up to 10 cycles (e.g., cycle 4, 6, 8, 10)', 'B. Cytokines and immune-phenotyping: pre-dose cycles 3 and 4 only', '14 Sep 2020', 'Astellas', 'Page 37 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '1', 'INTRODUCTION', '1.1', 'Urothelial Cancer', 'According to the International Agency for Research on Cancer (IARC), urothelial cancer kills', 'more than 165000 patients annually and is the ninth most common cancer overall worldwide.', 'Approximately 151000 new cases of urothelial cancer are diagnosed annually in Europe, with', '52000 deaths per year. Over 22000 new cases are diagnosed annually in Japan, with', '7600 deaths per year [Cancer Fact Sheets, 2017]. According to National Cancer Institute', 'estimates, over 79000 new cases of urothelial cancer were diagnosed in 2017, and more than', '16000 people died from the disease in the United States (US) [SEER Cancer Stat Facts, 2017].', 'First-line therapy for metastatic urothelial cancer in patients with sufficient renal function', 'consists of cisplatin-based combinations, like methotrexate, vinblastine, doxorubicin, and', 'cisplatin (MVAC) or gemcitabine plus cisplatin, which demonstrate overall response rates up', 'to 50%, including approximately 10 - 15% complete responses (CRs) [Bellmunt et al, 2011].', 'Despite initial chemosensitivity, patients are not cured and the outcome of metastatic', 'urothelial cancer after these regimens is poor: median time to progression is only 7 months', 'and median overall survival (OS) is 14 months. Approximately 15% of patients survive at', 'least 5 years and the prognosis is particularly poor among patients with visceral metastases', 'for whom the 5-year os rate is 7% [von der Maase, 2005].', 'For second line treatment, the small-molecule tubulin inhibitor vinflunine (JavlorR) is', 'approved only in Europe. The median OS is 6.9 months compared to a median OS of', '4.6 months for best supportive care [Bellmunt et al, 2009]. For decades, there were no major', 'changes to the treatment landscape with only cytotoxic chemotherapies available, until the', 'recent approvals of immune check point inhibitors (CPI) targeting the programmed death', '1/programmed death-ligand 1 (PD-1/PD-L1). As of May 2016, starting with the PD-L1', 'inhibitor atezolizumab, several CPIs have received FDA approval for urothelial cancer for', 'platinum-pretreated patients in the United States. Most approvals have been based on single', 'arm phase II data [Tecentriq Prescribing Information, Genentech, Apr 2017], [Opdivo', 'Prescribing Information, Bristol-Myers Squibb, September 2017], [Imfinzi Prescribing', 'Information, AstraZeneca, May 2017] and [Bavencio Prescribing Information, EMD Serono,', 'Mar 2017]. However, in 2017, results from the phase III trial KEYNOTE-045 demonstrated', 'that patients treated with pembrolizumab had significantly longer survival when compared', 'with the standard second-line chemotherapy [Bellmunt et al, 2017]. This led to the regular', 'approval of pembrolizumab as second line treatment for patients with locally advanced or', 'metastatic urothelial cancer (mUC; [Keytruda Prescribing Information, Merkk, Sep 2017]).', 'The approval was based on a median OS of 10.3 months for pembrolizumab compared with', '7.4 months with taxane chemotherapy or vinflunine [Bellmunt et al, 2017]. Marketing', 'approval of CPIs in Europe have followed and approvals in Asia are expected. Other PD-1', 'and PD-L1 inhibitors are currently being evaluated in clinical trials for urothelial cancer, as', 'first and second line therapy [Mullane & Bellmunt, 2016].', '14 Sep 2020', 'Astellas', 'Page 38 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}